Nelson Advisors: European Healthcare Technology and Digital Health Venture Capital Trends, Patterns and Future Market Signals

Nelson Advisors
5 hours ago
13 min read

Something fundamental has changed in European healthcare technology venture capital and it is not simply a matter of more money or less money. The market that emerged from the 2022–2024 correction is structurally different from the one that preceded it: fewer companies are being funded, but the survivors are being funded harder; capital that once sprayed across hundreds of point solutions now concentrates in a handful of flagship rounds; and artificial intelligence has quietly moved from being a differentiator worth a premium to a threshold requirement without which a company struggles to get a meeting at all.

For founders, investors and acquirers operating in European HealthTech, understanding this new shape of the market matters more than tracking any single quarterly funding figure. The headline numbers now tell contradictory stories depending on which slice you examine, European digital health funding in the first quarter of 2026 fell 44% year on year, yet first-half funding rose 60% over the same period. Both figures are accurate. Reconciling them is the key to understanding where this market is actually going.

We examine the data behind European healthcare technology and digital health venture capital through 2025 and the first half of 2026, draws out the durable patterns beneath the quarterly noise and identifies the forward signals that will define the market into 2027.

The Numbers: A Market That Rebounded, Then Concentrated

Start with the full-year 2025 picture. According to Galen Growth, Europe secured $6.2 billion in digital health venture funding in 2025, a 15% year-on-year increase that outpaced the mature North American market (which grew 7% to $19.5 billion) and Asia Pacific (up 14% to $2.4 billion). After three consecutive years in which Europe absorbed the downdraft of the global venture correction, 2025 was the year the region genuinely bucked the trend.

The geographic distribution of that capital was revealing. The United Kingdom led with $2.11 billion, consolidating its position as Europe's deepest healthcare technology capital pool. Finland, improbably, to those who have not followed the Nordic hardware-plus-software story, came second with $1.16 billion, driven overwhelmingly by Ōura's $900 million Series E. France followed at $731 million and Germany at $612 million. The 2025 mega-deal roster tells the same story of quality concentration: Ōura's $900 million, Isomorphic Labs' $600 million strategic round, Verdiva Bio's $411 million, Tubulis Technologies' €308 million, Neko Health's $260 million Series B, Amboss's $259 million and CMR Surgical's $200 million.

Then came 2026, and the picture split in two. The first quarter looked, on the surface, like a relapse: $1.2 billion across just 67 deals in Europe, down 44% in capital and 46% in deal count against Q1 2025. Yet the average deal size actually rose 8% to $21.1 million, and growth-stage funding dominated at $622 million, with late stage deals, which prior to 2025 were nearly unheard of in Europe, now a recurring feature of the landscape.

The second quarter resolved the apparent contradiction. Isomorphic Labs closed a $2.1 billion Series B, the largest digital health financing anywhere in the world in the first half of 2026 and Alan, the French health insurance platform, added $455.9 million in its Series G1. By the mid-year mark, European digital health funding stood at $5.9 billion for H1 2026, up 60% from $3.7 billion in H1 2025, even as deal count fell from 283 to 190. Europe achieved this while global digital health funding was essentially flat at $22.6 billion (against $21.4 billion in H1 2025) on a deal count that collapsed 38% globally, from 975 to 608.

Read together, the numbers describe a market where the median company faces the hardest fundraising environment in a decade while the top decile enjoys conditions reminiscent of 2021, without the tourists, and with far more diligence.

Pattern One: The Great Concentration

The single most important structural pattern in European digital health venture capital is concentration, of capital, of conviction and of outcomes.

Globally, the average digital health deal size reached $48.9 million in H1 2026, nearly triple the $18.4 million of H1 2023. Total capital deployed has fallen only 21% from the H1 2022 peak of $28.7 billion, but deal count has fallen 61% over the same period. The capital did not leave healthcare technology; it stopped being distributed democratically.

In Europe, this concentration is even more pronounced because the region's headline growth in H1 2026 was driven substantially by flagship AI-biology rounds rather than breadth across the ecosystem. Strip out Isomorphic Labs and Alan and the underlying European market looks much closer to the subdued Q1 picture: fewer deals, longer processes, higher evidential bars and a widening gulf between companies that clear the new threshold and those that do not.

Rock Health's H1 2026 data for the United States shows the same dynamic on the other side of the Atlantic: $7.4 billion across 244 US deals, with mega-deals of $100 million or more absorbing 45% of deployed capital while representing only 8% of transactions. This is not a European quirk. It is the new operating physics of digital health venture capital worldwide.

For founders, the practical implication is stark. The seed and Series A market still functions, early-stage capital in Europe reached $378 million in Q1 2026 alone, but the criteria have changed from promise to proof. Galen Growth characterises the current market as "a selectivity story, not a slowdown story": capital remains deployed, but it concentrates in ventures that can demonstrate enterprise adoption, clinical evidence and a credible path to profitability simultaneously, rather than any one of the three.

Pattern Two: AI Has Become the Table Stakes and AI-Biology the Prize

Two distinct AI dynamics are visible in the European data, and conflating them leads to bad strategy.

The first is that AI as a product capability has become a threshold requirement rather than a differentiator. Nelson Advisors' mid-2026 analysis notes that companies with proprietary, clinically validated algorithms command premium revenue multiples of 6x–8x, against a broader market range of 4x–6x, but undifferentiated "AI-enabled" software faces multiple compression and longer sale processes. Investors and acquirers have learned to distinguish between companies whose AI produces defensible clinical or economic outcomes and companies that have wrapped a large language model around a workflow. The former earn premiums; the latter increasingly cannot raise at all.

The second dynamic is the emergence of AI-biology as Europe's flagship category. Isomorphic Labs' $2.1 billion Series B, building on its $600 million 2025 round, is the most conspicuous data point, but the pattern extends through Verdiva Bio's $411 million raise, Tubulis's €308 million and a cohort of AI-driven drug discovery, clinical trial design and diagnostics companies (Biorce's $52.5 million Series A in clinical trial design being a representative early-stage example). Europe's strength in computational biology, structural biology and machine learning research, anchored by London, Cambridge, Basel, Munich and Paris, has given the region a genuine claim to global leadership in the single most capital hungry and potentially most valuable segment of healthcare AI.

The strategic signal for the broader ecosystem: capital is flowing to where AI touches biology and hard clinical evidence, not where it touches administrative convenience alone. The US market is consolidating administrative AI through M&A (revenue cycle management was the busiest American consolidation theme in H1 2026); Europe is building scientific AI through venture capital. These are different games with different exit paths.

Pattern Three: Europe Grows Up, The Late Stage Market Finally Exists

For most of the past decade, the standard criticism of European healthcare technology was that the region could start companies but could not scale them: seed and Series A capital was plentiful relative to the continent's size, but growth and late-stage rounds required a flight to American investors, an American flip, or an early trade sale.

That structural gap is now closing, and the data shows it clearly. In Q1 2026, growth-stage funding dominated European digital health at $622 million, with late-stage capital, nearly unheard of in Europe before 2025, contributing a further $116 million. Alan's Series G1, Oviva's $235 million Series D, DentalMonitoring's $100 million Series D and Ōura's continued mega-financing represent a class of company that simply did not exist at scale in Europe five years ago: digital health businesses raising their fifth, sixth or seventh institutional round on European soil.

There is, however, an important asterisk. US investors accounted for 62% of late-stage deal participation in European digital health in 2025. Europe's late-stage market exists, but it is substantially rented rather than owned. This cuts both ways: American capital validates European assets and imports pricing discipline learned in the world's deepest healthcare market, but it also means European scale-ups' valuations are underwritten by investors whose exit expectations are calibrated to US outcomes, US-scale IPOs, US strategic acquirers, US multiples.

Which leads directly to the question Galen Growth posed in its year-end analysis: 2025 was the year Europe got paid; 2026 is the year Europe must prove it was worth it. Raising capital is no longer the benchmark of success. Liquidity is. The inflated valuations of the 2025 vintage must eventually be justified by exits, and the exit environment examined below, remains the weakest link in the European chain.

Pattern Four: Geography, A Barbell of London and the Nordics, with France Compounding

The country-level pattern in European healthcare technology capital has three durable features.

First, the United Kingdom remains the centre of gravity: $2.11 billion in 2025, the largest single-country funding pool, the deepest bench of AI-biology companies (Isomorphic Labs, CMR Surgical in surgical robotics, Cera in tech-enabled care) and the most active M&A market. The UK's combination of DeepMind descended AI talent, globally credible clinical research infrastructure and a genomics ecosystem gives it a structural advantage in exactly the categories where capital is now concentrating.

Second, the Nordics punch extraordinarily far above their weight in consumer health hardware and preventive care. Finland's $1.16 billion in 2025, second in Europe, rests substantially on Ōura, while Sweden's Neko Health ($260 million Series B, co-founded by Daniel Ek) has made full-body preventive scanning a fundable category. The Nordic model of consumer-grade design applied to clinical-grade data has proven exportable and critically, exit-capable via the anticipated US public markets (Ōura has been discussed at an $11 billion valuation).

Third, France and Germany are compounding steadily rather than spectacularly: $731 million and $612 million respectively in 2025. France's champions cluster in insurance and care delivery (Alan, Doctolib), Germany's in medical knowledge, digital therapeutics and speciality care consolidation (Amboss's $259 million round; Ortivity's €200 million). Switzerland's density of medtech and diagnostics, DistalMotion, Gleamer's French-Swiss imaging axis, rounds out a continental picture in which partnership activity in Q1 2026 was led by the UK (35 strategic partnerships), France (28), Germany (9) and Switzerland (8).

The signal in the geography: capital follows regulatory sophistication and reimbursement clarity. The UK, France and Germany all now have functioning, if imperfect, digital health reimbursement pathways, and the countries without them are increasingly invisible in the funding data.

Pattern Five: What Gets Funded, B2B Models, Chronic Disease and the Metabolic Gold Rush

The clinical and commercial composition of European digital health funding has shifted decisively.

On business models, the centre of gravity has moved to enterprise sales. Globally in H1 2026, B2B models attracted $12.7 billion across 332 deals against $6.4 billion for B2C across 173 and Europe's B2C successes (Ōura, Neko) are the hardware-anchored exceptions that prove the software rule. Selling to health systems, insurers and pharmaceutical companies is harder and slower than selling to consumers, but it is where durable revenue and strategic exit interest live.

On clinical areas, Q1 2026 European funding concentrated in cardiovascular disease ($294 million), diabetes and nutrition ($261 million), chronic disease management ($260 million) and nephrology ($254 million), a portrait of a market backing the management of expensive, prevalent, lifelong conditions rather than episodic or wellness use cases. Patient Solutions was the leading cluster at $298 million (25% of the quarter), with Medical Diagnostics at $222 million.

The metabolic category deserves its own mention. Oviva's $235 million Series D, the largest European digital health round of Q1 2026, is a digitally delivered obesity and type 2 diabetes care company riding the same GLP-1 wave that made weight management the second-best-funded clinical indication in the US in H1 2026 (behind mental health, top-funded for the seventh consecutive year, per Rock Health).

The GLP-1 ecosystem, titration support, behavioural wraparound, nutrition therapy, de-prescribing, is generating an entire stratum of fundable European companies and Nelson Advisors identifies obesity and metabolic care, alongside mental health, AI-powered diagnostics and imaging, femtech and preventive care, as the priority subs ectors where capital and M&A interest are concentrating into 2027.

The Exit Question: M&A Is the Only Door That Is Open

If funding tells the story of conviction, exits tell the story of proof and here Europe's picture is improving from a low base but remains the ecosystem's binding constraint.

Globally, H1 2026 produced 82 digital health M&A transactions worth $5.15 billion in disclosed value, against a single IPO (Generate Biomedicines' $400 million listing). In Europe specifically, Q1 2026 delivered 13 M&A transactions with $552 million in disclosed value, led by Kaia Health's $285 million sale and Gleamer's $267 million acquisition, respectable mid-market outcomes, and precisely the €25–250 million transaction range where Nelson Advisors expects the bulk of European deal activity to concentrate.

The composition of buyers is broadening in an encouraging way. Strategic acquirers remain the anchor, paying for proven assets with regulatory clearances and defensible data. Private equity has moved from opportunistic to programmatic, with buy and build platforms dominating sponsor activity in speciality care, diagnostics networks and healthcare software. Pharmaceutical companies are acquiring digital adjacencies to wrap services around therapeutic franchises, nowhere more actively than in metabolic care. And a newer phenomenon, the AI-native merger, is pairing legacy assets that own workflow, data and distribution with modern AI capabilities that own the technology curve.

The US comparison is instructive for what lies ahead. American digital health M&A ran at 115 transactions in H1 2026, with Q2's 71 deals the busiest quarter since late 2021, and Hinge Health's post-IPO performance (doubling its offer price on 23% free cash flow margins) alongside Oura's anticipated $11 billion listing has cracked the public-market door open. Europe historically follows US exit windows with a 12–18 month lag. If that pattern holds, 2027 is the year the European exit story either materialises or the 2025 valuation vintage starts to look expensive.

Future Market Signals: What to Watch from Here

Distilling the data into forward-looking signals, six stand out for anyone allocating capital, building a company or preparing a transaction in European healthcare technology.

1. H2 2026 should be a consolidation half, not a funding half

With portfolio pruning underway at large incumbents, sponsor dry powder committed to buy-and-build platforms, and a large cohort of 2021–2022 vintage companies reaching the end of their runway extensions, the conditions point to materially higher M&A activity in the second half of 2026, concentrated in carve-outs, bolt-ons and club deals between private equity and corporate partners in the €25–250 million range. Watch the monthly deal count, not the funding total, as the health indicator for the ecosystem.

2. The liquidity test arrives in 2027

The 62% US participation rate in European late-stage rounds is a loan against future exits. If Ōura's anticipated listing and the reopening US IPO window pull one or two European champions onto public markets by 2027, the flywheel, exits repricing the asset class upward, returning capital to European funds, deepening the domestic late-stage pool, starts turning. If not, expect down-rounds, structured secondaries and an acceleration of trade sales at valuations below the 2025 marks.

3. The partnership slowdown is an early-warning indicator worth respecting

European digital health partnerships fell 32% year on year in H1 2026 (from 412 to 281), even as funding rose. Partnerships are the leading edge of enterprise revenue; funding is a lagging vote on past evidence. A sustained divergence between the two, capital up, commercial adoption activity down, would suggest the flagship rounds are running ahead of the market's underlying absorptive capacity. Encouragingly, healthcare providers accounted for the largest share of strategic partnerships (24% in Europe in Q1 2026 and the largest single category globally), evidence that European health systems are finally catching up to US adoption patterns.

4. Reimbursement pathways will keep redrawing the funding map

Germany's DiGA framework, France's PECAN pathway and the NHS's evolving procurement and AI deployment programmes are becoming the de facto gatekeepers of venture fundability. Countries that industrialise reimbursement for digital care and AI diagnostics will pull capital toward their ecosystems; those that do not will watch their founders incorporate elsewhere. The Q1 2026 partnership league table, UK 35, France 28, Germany 9, already reflects this sorting.

5. Obesity and metabolic care is the single most investable theme of the cycle and the most crowded

The GLP-1 ecosystem has done for metabolic health what teletherapy did for mental health in 2020–2021: created an entire fundable category almost overnight. Oviva's $235 million round shows European scale is achievable here. The pattern from the mental health cycle also carries a warning, category leaders will compound, but the middle of the pack will consolidate at unremarkable prices within three years.

6. The bar will not come back down.

Perhaps the most important signal is the absence of one: nothing in the data suggests a return to the 2021 pattern of broad, shallow capital deployment. Average deal sizes tripling while deal counts fall by more than half is not a cyclical anomaly to be waited out; it is the maturity era of digital health, in Galen Growth's phrase. Companies should plan financing strategy on the assumption that every future round requires enterprise adoption, clinical evidence and unit economics simultaneously and that the alternative to clearing that bar is not a smaller round but a strategic process.

Conclusion: A Smaller Door into a Bigger Room

European healthcare technology venture capital in 2026 rewards a different company than it did in 2021. The market is writing fewer, larger cheques to businesses that have already proven something, clinically, commercially or both and it is doing so with a confidence in Europe's scientific base, particularly in AI-biology, that has no precedent in the region's digital health history.

Europe outgrew North America in funding terms in 2025 and outgrew it again, dramatically, in H1 2026. The capital, the talent and the buyer interest are all present.

What remains unproven is the last mile: liquidity. The 2025–2026 vintage of European mega-rounds has been priced, substantially by American investors, on the expectation of exits that the European ecosystem has not yet reliably delivered. The next eighteen months, the anticipated H2 2026 consolidation wave, the 2027 IPO window, the maturing €25–250 million M&A mid-market, will determine whether this cycle ends as the moment European HealthTech came of age, or as another expensive lesson in the difference between raising money and returning it.

The door into this market is smaller than it has ever been. The room on the other side is bigger. That, more than any quarterly funding figure, is the trend, the pattern and the signal.

Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Follow Nelson Advisors LinkedIn Page > https://www.linkedin.com/company/nelson-advisors/

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions. https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

#VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada